Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (GAG-POL-NEF-MULTICLADE ENV) in HIV-1 Infected Subjects Treated During Acute HIV Infection
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2015
At a glance
- Drugs VRC-HIVDNA009-00-VP (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 03 Dec 2007 Status changed from in progress to completed.
- 12 Dec 2005 New trial record.